Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basket of Baskets for molecularly selected advanced solid tumors
NL-OMON54705Phase 2Recruiting
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab and futibatinib in Nonhematologic neoplasms (3 arms), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoint: Overall response rate. Started Mar 2019; status: recruiting.
02
Drugs
atezolizumabfutibatinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON54705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54705.